What Are the Different Types of Botulinum Toxin?

Botulinum toxin is not a single, uniform substance. Scientists traditionally classify it into seven main serotypes—types A, B, C, D, E, F and G—according to their biological and immunological characteristics.

Although these types belong to the same broader toxin family, they interact with nerve cells in slightly different ways. Only a small number have established therapeutic applications, and botulinum toxin type A is the form most commonly discussed in aesthetic medicine.

Understanding the different types of botulinum toxin can make the science behind these medicines less confusing. It also explains why formulations, potency units and doses cannot be treated as interchangeable.

This article provides general educational information only. Botulinum toxin is a prescription-only substance in Australia and can only be considered following an appropriate consultation with a qualified health practitioner.

How Does Botulinum Toxin Work?

Nerves communicate with muscles by releasing a chemical messenger called acetylcholine. This messenger travels across the small space between a nerve and a muscle, instructing the muscle to contract.

Botulinum neurotoxins temporarily interfere with the release of acetylcholine at selected nerve endings. When used therapeutically in carefully controlled amounts, this reduces activity in the targeted muscle or gland.

Each serotype acts on proteins involved in acetylcholine release. These proteins form part of the SNARE complex—a group of proteins that helps nerve cells release chemical messengers.

The different types do not all target the same SNARE protein:

Types A and E act on a protein called SNAP-25.
Types B, D, F and G act on a protein called VAMP, also known as synaptobrevin.
Type C can affect SNAP-25 and another protein called syntaxin.

These differences influence how each serotype behaves. However, they do not mean that patients can select a type based on a simple comparison. Clinical suitability depends on the approved medicine, the condition being addressed and an individual medical assessment.

What Are Botulinum Toxin Serotypes?

A serotype is a distinct variation of a microorganism or biological substance that can be identified by the way it reacts with antibodies. In simple terms, types A to G are related, but the immune system recognises each as biologically different.

Each serotype may also contain several subtypes. Subtypes have variations in their amino acid sequences—the molecular building blocks of proteins. These differences can affect characteristics such as receptor binding, biological activity and duration under experimental conditions.

Researchers have also identified additional toxin-like variants and mosaic forms through genetic analysis. However, the traditional A-to-G classification remains the most useful framework for explaining the established botulinum toxin serotypes.

The Different Types of Botulinum Toxin

Botulinum Toxin Type A

Type A is the most widely studied botulinum toxin serotype and the type most commonly used in established clinical formulations.

In medicine, type A has applications across several fields, including neurology, ophthalmology and the management of certain muscle or gland-related conditions. It is also the serotype commonly associated with aesthetic indications involving selected facial muscles.

Type A temporarily reduces signalling between targeted nerves and muscles. In an aesthetic setting, its effect on muscle movement may influence the appearance of certain expression-related lines. It does not fill the skin, replace lost volume or directly stimulate collagen production.

There are multiple prescription formulations based on type A. While they share the same general serotype, they may differ in areas such as:

Manufacturing and purification processes
Protein composition
Excipients, which are inactive ingredients used in a formulation
Storage and preparation requirements
Approved indications
Potency testing
Recommended dosing

These differences are clinically important. A practitioner cannot assume that two type A formulations will behave identically or use the same number of units.

Botulinum Toxin Type B

Type B also reduces acetylcholine release, but it acts on a different part of the nerve-release system from type A. Type B targets VAMP rather than SNAP-25.

Therapeutic type B formulations have been used in some jurisdictions for selected medical conditions, particularly certain forms of involuntary muscle contraction. Their availability and approved indications vary between countries.

Type B is not simply a stronger or weaker version of type A. It is a separate serotype with different biological characteristics. Its dose, potency units and clinical profile cannot be directly converted from those of type A.

Research has explored type B as a possible option in certain situations where a person has developed a reduced response to type A. This is a specialised medical consideration rather than a routine aesthetic choice.

Botulinum Toxin Type C

Type C mainly affects animals and has been associated with botulism in birds and other species. Unlike most other serotypes, it can act on two components of the nerve-release machinery: SNAP-25 and syntaxin.

Type C has primarily been studied in laboratory and research settings. It does not have an established role in routine human aesthetic treatment.

Botulinum Toxin Type D

Type D is also predominantly associated with botulism in animals. It acts on VAMP, one of the proteins needed for the release of acetylcholine.

Researchers have studied type D to understand its biological behaviour and potential applications. It is not an established option in routine human aesthetic practice.

Botulinum Toxin Type E

Type E can cause human botulism and is frequently associated with aquatic or marine food sources in naturally occurring cases. At a cellular level, it acts on SNAP-25, as type A does, but cleaves the protein at a different location.

Experimental research suggests that its biological activity may begin and resolve differently from type A. However, type E does not have an established role in routine aesthetic treatment.

Botulinum Toxin Type F

Type F is a less common cause of human botulism. Like types B, D and G, it acts on the VAMP protein.

Its properties have attracted research interest, including whether its different biological profile could have specific clinical applications. It is not routinely used in aesthetic medicine.

Botulinum Toxin Type G

Type G is rare and remains primarily relevant to microbiological and laboratory research. It also targets VAMP but has different binding and biological characteristics from the other serotypes.

It has no established role in routine aesthetic treatment.

Serotypes and Formulations Are Not the Same Thing

The terms serotype and formulation describe different things.

A serotype is a biological category, such as type A or type B. A formulation is a specific prescription medicine manufactured using one of those serotypes.

Several formulations can therefore belong to the same serotype while differing in their production, composition, potency testing and approved uses. This is why knowing that two medicines are both based on type A does not make them interchangeable.

This distinction is particularly important when reading information online. A statement about type A as a scientific category may not apply equally to every formulation made from that serotype.

Why Botulinum Toxin Units Cannot Be Compared Directly

Botulinum toxin potency is measured in biological units. These are not standard units like milligrams, and they do not describe the physical weight of the medicine.

Manufacturers determine potency using tests specific to their formulations. As a result, one unit of one formulation is not necessarily equivalent to one unit of another.

There is no universal conversion ratio that patients should use to compare doses. A larger number of units does not automatically mean that a medicine is stronger, more effective or more suitable.

Safe treatment planning requires knowledge of the individual formulation, its approved information and the patient’s clinical circumstances.

What Determines Which Formulation Is Considered?

The scientific type is only one part of treatment planning. A qualified practitioner must first determine whether a prescription treatment is appropriate at all.

An individual assessment may consider:

The patient’s medical history
Current medicines and supplements
Previous procedures or facial surgery
Allergies
Pregnancy or breastfeeding
Neuromuscular conditions
Infection or inflammation near a proposed treatment area
Facial anatomy and natural asymmetry
Muscle strength and movement patterns
The concern being assessed
The patient’s expectations and treatment preferences

The aim of a consultation should not be to choose a product from an online list. It should be to understand the patient, assess the concern and discuss suitable options, limitations and risks.

Are There Risks and Side Effects?

All prescription medicines carry potential risks. Possible effects associated with botulinum toxin type A may include redness, swelling, bruising, headache, local discomfort, temporary muscle weakness, facial asymmetry or drooping of a nearby feature.

The precise risks depend on factors including the area treated, dose, formulation, injection technique and individual anatomy.

Although uncommon, more serious complications can occur if the toxin’s effect spreads beyond the intended area. Symptoms such as difficulty swallowing, speaking or breathing require urgent medical attention.

A person should tell their practitioner about all health conditions, medicines and supplements. Particular caution may be required for people with certain neuromuscular disorders, infection at a proposed treatment site, previous reactions to a formulation, or medicines that affect muscle and nerve function.

Pregnancy and breastfeeding should also be discussed during the medical consultation.

Why Practitioner Assessment Matters

Understanding the different types of botulinum toxin provides useful background, but it cannot determine whether treatment is safe or appropriate for an individual.

Facial structure and muscle movement vary considerably. The same visible line may have different contributing factors in different people, including repeated muscle movement, skin quality, sun exposure, collagen loss or changes in facial volume. A treatment that reduces muscle activity will not address every cause of a line or wrinkle.

A considered consultation should include an assessment of anatomy and movement, a discussion of alternatives and realistic information about possible outcomes. Patients should also understand who will prescribe and administer the medicine, what follow-up is available and how complications would be managed.

In Australia, patients can check whether a practitioner is registered through the Australian Health Practitioner Regulation Agency.

A Consultation-First Approach

At a doctor-led aesthetic clinic, education and individual assessment should come before treatment selection. The presence of several serotypes and formulations does not mean that patients need to decide between them independently.

A personalised consultation allows the practitioner to explore the patient’s concerns, health history and expectations before discussing whether any treatment is appropriate. It also creates space to explain the limitations of treatment and consider non-prescription or non-procedural alternatives where relevant.

For patients in Bulleen, Eastern Melbourne and surrounding areas, the priority should be informed decision-making rather than choosing a medicine based on trends, unit counts or online comparisons.

Conclusion

The different types of botulinum toxin are traditionally classified as serotypes A through G. While they all interfere with nerve signalling, they act on different cellular proteins and have distinct biological characteristics.

Type A is the most widely studied and clinically relevant serotype in aesthetic medicine. Type B has therapeutic uses in certain medical settings, while types C, D, E, F and G are primarily associated with research, natural botulism or animal disease rather than routine aesthetic care.

Even within the same serotype, prescription formulations may differ. Their units, doses and clinical instructions cannot be directly compared.

Scientific information can help patients ask better questions, but it does not replace an individual medical assessment. Decisions about prescription treatment should always be made with an appropriately qualified health practitioner.

A Thought to Consider

The most useful question may not be, “Which type is best?” but rather, “What is contributing to my concern, and what options are appropriate for me?”

A thoughtful consultation should help answer that question before any treatment is considered.

References

Publication note: This draft has been kept factual, balanced and free from product or brand comparisons. Because it names a Schedule 4 prescription substance on a cosmetic clinic website, MAEC should still have the final page—including surrounding links, images and calls to action—reviewed for compliance with the latest TGA and Ahpra requirements before publication.